Key result
This review discusses the current state of clinical and preclinical development of gene therapy for heart disease, including vector technology and delivery strategies.
This review provides an overview of the current state of gene therapy for heart disease, including molecular targets, vector technologies, and delivery strategies.
Gene therapy for heart disease remains investigational; extends vector and delivery insights but leaves clinical translation open.
Despite the numerous hurdles that gene therapy has encountered along the way, clinical trials over the last few years are showing promising results in many fields of medicine, including cardiology, where many targets are moving toward clinical development. In this review, the authors discuss the current state of the art in terms of clinical and preclinical development. They also examine vector technology and available vector-delivery strategies.
No takes yet. Share an insight, caveat, or question.
Scimia et al. (2013) conducted a review in Heart disease. Gene therapy was evaluated. This review discusses the current state of clinical and preclinical development of gene therapy for heart disease, including vector technology and delivery strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: